TENCENT
00700
TME-SW
01698
XIAOMI-W
01810
ALI HEALTH
00241
KUAISHOU-W
01024
(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|
Cash flow from operating activities | ||||||||||
Earning before tax | ---- | -570.71%-884.96M | ---- | -71.89%188.01M | ---- | 171.15%668.7M | ---- | -58.28%246.62M | ---- | -51.78%591.12M |
Profit adjustment | ||||||||||
Interest (income) - adjustment | ---- | 9.41%-39.06M | ---- | 4.80%-43.12M | ---- | 12.68%-45.3M | ---- | 3.78%-51.87M | ---- | 7.18%-53.91M |
Dividend (income)- adjustment | ---- | 24.47%-13.13M | ---- | -180.97%-17.38M | ---- | 82.20%-6.19M | ---- | -85.29%-34.76M | ---- | 33.94%-18.76M |
Attributable subsidiary (profit) loss | ---- | -191.58%-22.1M | ---- | 188.14%24.13M | ---- | 38.09%-27.37M | ---- | -37.36%-44.22M | ---- | 47.87%-32.19M |
Impairment and provisions: | ---- | 3,690.63%598.69M | ---- | --15.79M | ---- | ---- | ---- | ---- | ---- | ---- |
-Impairment of property, plant and equipment (reversal) | ---- | 238.26%53.43M | ---- | --15.79M | ---- | ---- | ---- | ---- | ---- | ---- |
-Other impairments and provisions | ---- | --545.27M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Revaluation surplus: | ---- | 226.85%301.61M | ---- | 37.08%-237.78M | ---- | -370.57%-377.88M | ---- | 213.79%139.66M | ---- | 71.29%-122.73M |
-Fair value of investment properties (increase) | ---- | 225.77%297.48M | ---- | 37.61%-236.53M | ---- | -378.38%-379.14M | ---- | 213.65%136.2M | ---- | 72.52%-119.84M |
-Derivative financial instruments fair value (increase) | ---- | ---- | ---- | ---- | ---- | -128.80%-1.72M | ---- | 1,184.30%5.97M | ---- | -93.04%465K |
-Other fair value changes | ---- | 431.78%4.13M | ---- | -141.84%-1.25M | ---- | 218.79%2.98M | ---- | 25.30%-2.51M | ---- | -279.75%-3.36M |
Asset sale loss (gain): | ---- | -46.50%3.46M | ---- | 76.79%6.46M | ---- | 98.59%3.65M | ---- | 485.99%1.84M | ---- | -84.87%314K |
-Loss (gain) on sale of property, machinery and equipment | ---- | -46.50%3.46M | ---- | 76.79%6.46M | ---- | 98.59%3.65M | ---- | 485.99%1.84M | ---- | -84.87%314K |
Depreciation and amortization: | ---- | 2.26%104.66M | ---- | 35.71%102.34M | ---- | -0.59%75.41M | ---- | 290.58%75.86M | ---- | 52.31%19.42M |
Financial expense | ---- | 133.79%138.5M | ---- | 151.86%59.24M | ---- | -45.52%23.52M | ---- | -4.63%43.17M | ---- | 136.72%45.27M |
Special items | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---81.35M | ---- | ---- |
Operating profit before the change of operating capital | ---- | 92.11%187.67M | ---- | -68.94%97.69M | ---- | 6.65%314.55M | ---- | -31.17%294.95M | ---- | -43.53%428.54M |
Change of operating capital | ||||||||||
Inventory (increase) decrease | ---- | 156.88%157K | ---- | 96.97%-276K | ---- | -867.57%-9.11M | ---- | -69.49%1.19M | ---- | 196.72%3.89M |
Developing property (increase)decrease | ---- | 69.23%-69.59M | ---- | 17.06%-226.13M | ---- | -344.62%-272.63M | ---- | 93.15%-61.32M | ---- | -160.86%-895.42M |
Accounts receivable (increase)decrease | ---- | 8.59%-18.72M | ---- | 59.43%-20.48M | ---- | -710.36%-50.48M | ---- | 201.94%8.27M | ---- | -83.69%2.74M |
Accounts payable increase (decrease) | ---- | 94.50%-5.19M | ---- | -293.36%-94.24M | ---- | 169.74%48.74M | ---- | -127.25%-69.88M | ---- | 202.30%256.4M |
Derivative financial instruments (increase) decrease | ---- | ---- | ---- | ---- | ---- | 99.27%-88K | ---- | ---12.01M | ---- | ---- |
Special items for working capital changes | ---- | -44.73%34.97M | ---- | -49.26%63.27M | ---- | 18.21%124.69M | ---- | 143.14%105.49M | ---- | -134.56%-244.55M |
Cash from business operations | ---- | 171.77%129.3M | ---- | -215.74%-180.16M | ---- | -41.63%155.67M | ---- | 159.47%266.69M | ---- | -150.64%-448.41M |
Other taxs | ---- | 88.56%-12.37M | ---- | -187.92%-108.09M | ---- | 44.98%-37.54M | ---- | 66.46%-68.24M | ---- | -27.22%-203.46M |
Dividend received - operating | ---- | -24.47%13.13M | ---- | 180.97%17.38M | ---- | -82.20%6.19M | ---- | 85.29%34.76M | ---- | -33.94%18.76M |
Interest received - operating | ---- | -9.41%39.06M | ---- | -4.80%43.12M | ---- | -12.68%45.3M | ---- | -3.78%51.87M | ---- | -20.48%53.91M |
Special items of business | 47.41%84.29M | ---- | 205.78%57.18M | ---- | -145.67%-54.06M | ---- | 364.19%118.36M | ---- | 104.21%25.5M | ---- |
Net cash from operations | 47.41%84.29M | 174.26%169.12M | 205.78%57.18M | -234.28%-227.75M | -145.67%-54.06M | -40.50%169.61M | 364.19%118.36M | 149.22%285.08M | 104.21%25.5M | -170.49%-579.2M |
Cash flow from investment activities | ||||||||||
Dividend received - investment | -5.99%1.84M | -37.89%3.72M | -35.77%1.95M | -67.23%5.99M | -79.45%3.04M | --18.27M | --14.79M | ---- | ---- | ---- |
Loan receivable (increase) decrease | 327.61%40.24M | -84.42%15.89M | -58.33%9.41M | 183.43%101.95M | -37.22%22.58M | 80.33%35.97M | 94.40%35.97M | 15.15%19.95M | 52.60%18.5M | 144.38%17.32M |
Decrease in deposits (increase) | -2,259.25%-128.43M | -108.82%-7.91M | -78.43%5.95M | 560.01%89.71M | 555.73%27.58M | 79.85%-19.5M | 106.92%4.21M | -2,090.30%-96.81M | 87.55%-60.81M | -98.58%4.86M |
Purchase of fixed assets | 81.83%-6.21M | 0.29%-42.3M | -132.29%-34.14M | -139.33%-42.42M | -131.10%-14.7M | -82.31%-17.72M | -111.44%-6.36M | 33.45%-9.72M | 46.16%-3.01M | -34.98%-14.61M |
Acquisition of subsidiaries | ---- | ---425.29M | ---425.29M | ---- | ---- | ---111.56M | ---- | ---- | ---- | ---- |
Recovery of cash from investments | 75.75%5.8M | 55.66%4.18M | 309.81%3.3M | -99.25%2.69M | --805K | 2,189.41%357.47M | ---- | -73.51%15.61M | ---- | 39.37%58.94M |
Cash on investment | -379.70%-5.51M | 71.80%-80.72M | 99.59%-1.15M | -59.38%-286.21M | -4.07%-280.34M | -143.76%-179.58M | -1,136.80%-269.39M | -521.32%-73.67M | -446.71%-21.78M | -66.02%-11.86M |
Other items in the investment business | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 65.23%-39.31M | ---- | -206.58%-113.06M |
Net cash from investment operations | 79.03%-92.27M | -315.01%-532.43M | -82.53%-439.97M | -253.94%-128.29M | -9.17%-241.04M | 145.31%83.34M | -229.06%-220.78M | -215.01%-183.95M | 87.07%-67.1M | -120.15%-58.4M |
Net cash before financing | 97.91%-7.98M | -2.04%-363.3M | -29.72%-382.79M | -240.76%-356.04M | -188.13%-295.1M | 150.14%252.95M | -146.22%-102.42M | 115.86%101.12M | 96.30%-41.6M | -157.36%-637.6M |
Cash flow from financing activities | ||||||||||
New borrowing | 243.27%1.3B | -35.24%499.92M | 0.49%377.83M | 10.44%772M | 135.00%376M | 74.15%699M | -10.11%160M | -79.26%401.38M | -79.60%178M | 3,642.48%1.94B |
Refund | -819.35%-263.38M | 24.28%-308.14M | 65.77%-28.65M | 47.83%-406.94M | -144.39%-83.69M | -75.78%-780.07M | 70.80%-34.24M | 65.45%-443.78M | 63.18%-117.28M | -210.83%-1.28B |
Interest paid - financing | -56.48%-87.36M | -154.66%-133.81M | -225.57%-55.83M | -148.15%-52.54M | -55.62%-17.15M | 48.54%-21.17M | 58.27%-11.02M | 8.26%-41.15M | -50.61%-26.41M | 3.04%-44.86M |
Dividends paid - financing | 15.00%-64.36M | 36.23%-117.36M | 28.57%-75.72M | -13.06%-184.05M | -12.00%-106M | 23.95%-162.79M | 39.82%-94.65M | 19.23%-214.05M | 13.46%-157.26M | -9.10%-265.01M |
Net cash from financing operations | 307.59%881.28M | -149.57%-62.14M | 29.07%216.21M | 146.68%125.36M | 814.34%167.52M | 11.33%-268.52M | 114.62%18.32M | -190.08%-302.83M | -135.56%-125.29M | 151.67%336.19M |
Effect of rate | -147.68%-7.84M | 70.15%-14.37M | 85.29%-3.17M | -433.76%-48.15M | -770.63%-21.53M | -62.64%14.43M | 136.32%3.21M | 240.21%38.61M | -46.81%-8.84M | 52.98%-27.54M |
Net Cash | 624.27%873.29M | -84.43%-425.45M | -30.56%-166.57M | -1,381.23%-230.69M | -51.70%-127.58M | 92.28%-15.57M | 49.61%-84.1M | 33.08%-201.71M | 78.40%-166.88M | -165.40%-301.4M |
Begining period cash | -27.54%1.16B | -14.87%1.6B | -14.87%1.6B | -0.06%1.88B | -0.06%1.88B | -8.00%1.88B | -8.00%1.88B | -13.89%2.04B | -13.89%2.04B | 20.46%2.37B |
Cash at the end | 41.72%2.02B | -27.54%1.16B | -17.34%1.43B | -14.87%1.6B | -3.86%1.73B | -0.06%1.88B | -3.66%1.8B | -8.00%1.88B | 17.23%1.86B | -13.89%2.04B |
Cash balance analysis | ||||||||||
Bank deposits | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -13.89%2.04B |
Cash and cash equivalent balance | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -13.89%2.04B |
Currency Unit | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD |
Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
Auditor | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.